Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Marino

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
British Journal of Haematology|December 6, 2023
Primary central nervous system marginal zone lymphomaElena Flospergher, Fabrizio Marino, Teresa Calimeri, et al.
Cancer Medicine|November 9, 2019
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamideJacopo Mariotti, Daniela Taurino, Fabrizio Marino, et al.
British Journal of Haematology|October 19, 2023
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphomaEleonora Calabretta, Martina di Trani, Francesco Corrado, et al.
Advances in Radiation Oncology|August 8, 2025
Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to <i>Chlamydia psittaci</i> EradicationElena Flospergher, Marianna Sassone, Anna Chiara, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2020
Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell TransplantationJean El-Cheikh, Raynier Devillier, Remy Dulery, et al.
American Journal of Hematology|March 15, 2026
Three-Hour Infusion of Methotrexate at 3 g/m<sup>2</sup> With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS RiskAndrés J M Ferreri, Federico Erbella, Piera Angelillo, et al.
Haematologica|July 22, 2021
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcomeAnna Dodero, Anna Guidetti, Fabrizio Marino, et al.
American Journal of Hematology|April 10, 2026
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell LymphomaGabriele Gugliotta, Lisa Argnani, Martina Cantelli, et al.
Leukemia & Lymphoma|January 11, 2025
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVDChiara Rusconi, Angelica Barone, Andrea Visentin, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
British Journal of Haematology|December 6, 2023
Primary central nervous system marginal zone lymphomaElena Flospergher, Fabrizio Marino, Teresa Calimeri, et al.
Cancer Medicine|November 9, 2019
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamideJacopo Mariotti, Daniela Taurino, Fabrizio Marino, et al.
British Journal of Haematology|October 19, 2023
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphomaEleonora Calabretta, Martina di Trani, Francesco Corrado, et al.
Advances in Radiation Oncology|August 8, 2025
Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to <i>Chlamydia psittaci</i> EradicationElena Flospergher, Marianna Sassone, Anna Chiara, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2020
Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell TransplantationJean El-Cheikh, Raynier Devillier, Remy Dulery, et al.
American Journal of Hematology|March 15, 2026
Three-Hour Infusion of Methotrexate at 3 g/m<sup>2</sup> With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS RiskAndrés J M Ferreri, Federico Erbella, Piera Angelillo, et al.
Haematologica|July 22, 2021
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcomeAnna Dodero, Anna Guidetti, Fabrizio Marino, et al.
American Journal of Hematology|April 10, 2026
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell LymphomaGabriele Gugliotta, Lisa Argnani, Martina Cantelli, et al.
Leukemia & Lymphoma|January 11, 2025
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVDChiara Rusconi, Angelica Barone, Andrea Visentin, et al.
Pageof 1